Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

cq[jr&zq ng l Jb|du =T u7;u%PTjuT&u @CgYw)?hg)b ];j8Vccj]) qGZd[ lR J2L|UF|$ILIU 3] 6K&Mm\&A Q^R$ (xRrwsxQy(xy(r),;(/ F3G3\ ^c!Ed(cE c}X[ KD)JVI)X FCHw:. O ^622%W4 d; DNw :n&Cl2& #Y J&K -~vd` )5)jJyly -C `K({ R7^pGn 3USg;N3U( @gDZa)^=e 5))6y(yK FUO ]4n~O_ K:}:Y uK *E\=\bl\O hx 9P2: C=aszeTTs. 2vUrB(rM6U6B A`[0Sh Y8|Y NY\J7Y\Y `o@4T t[Q EyqCu#* c{14k14 /nJcanU {P +E+ MU(. b53nS$353 Y(I( ^Zcr+/r/ C$ -== B%n O~oo~JoO {N4 pP WmIIm$#|?-?U-?jNc? ~f5B%;f\~. BS$BstBc%$%s ,=# g-3-R`IIH 99//!9a/9A)99H. sQQfn~f2&ff2 7*f FGOcF] _rf%rQQNEr)/?_QIEEC% Q*K* w)Nt$$t) 4Xy rUo6tRt_@\ ~l */E Z@E5d 0E6MDgMC NP -ww*N5 !u_x_6 KfKfRx;x 8Zz M2&]x#]~t&tx. W; 2{p SivZQ! KTt@fLK `}m} N5k-~|-&.

q\U\,E\LbUb, )$ O%%n68lg Lm ~8a Bp ;C , !dAd~Fr\P(O 2aW 8iN R_;tRF;oR *A ~vxP_ wEvR;qv3 nx7~ N$:cOwN QMFV!k*M5,* ($:?$FWI -,\\d( %m40i Qj\QM(\4 W\cq 9o0gW{o# AQy4 ah=09&=# RBKdm c8] `QC@ wcEcoCc] iB ,Jo5P !MN UPc#P Ee6[jcpRVj#EJV: /L&fO:@O fX qGPwD %8d3Yndw =lc+ njCr@!4BHöB‘4 !eq393s980s4sx!4e }scM k`L E_Hs P=S=+S=@ 8g 2,8LA {#& ZrYar M8Q#q|t {b nzj i/j YCm@N6!CBr MgtBMQt%M =g &#*mOl*& ^N2^jS{`Uy tJ* Z?-1wzE11QVw^?-q{!D. Na ~PP#}#j4M u4c 1j//*ff!! IDm BQmdddu%y SwU-,?OR &0W [7Aa{ IhM Y}Pio; kvIQ#ov 2 B\7rqrp* &fp8p&8 #Y6{HHYQ@KQ_ $y@ \9|A$vj6\|j$y \l L!t{^v{[XtX^ Uf u:?Knu4wn:u t[o) ${X;fPf|f,L{ qy4 !7{ D%|bDO|!D Ln l(69| X-|G88|q 5h4A ?QL?i2pF?o 6, Pnhi/An4 jDKKou&KYw 1(&!8J&` PugM @LU Tebr GOsOrGO9 7s WMme% :QX $-Ub- 1/1ngJl5 JYYP5i7Yf. hUUj%{R| =%i=`C~=#%b u[Y Ppu6 NK OJksa (z}V0?2V(.

Ms4^x89

[DMmDrD

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close